Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Auditory system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    82 result(s) found for: Auditory system. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-002672-25 Sponsor Protocol Number: STR001-201 Start Date*: 2015-11-18
    Sponsor Name:Strekin AG
    Full Title: A Phase II multicenter, placebo-controlled, proof-of-concept study evaluating the safety, and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear ...
    Medical condition: Prevention of Hearing Loss after Cochlear Implant Surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001836-69 Sponsor Protocol Number: Vort-MCI_001 Start Date*: 2021-09-17
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging
    Medical condition: Mild cognitive impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003117-28 Sponsor Protocol Number: EPU-P77 Start Date*: 2014-11-03
    Sponsor Name:
    Full Title: Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study
    Medical condition: memory impairment in patients with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10027174 Memory impaired LLT
    17.0 10029205 - Nervous system disorders 10027175 Memory impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001337-86 Sponsor Protocol Number: 104-201403 Start Date*: 2014-07-11
    Sponsor Name:Otonomy Inc.
    Full Title: A 6-month, prospective, randomized, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease, foll...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005346-20 Sponsor Protocol Number: PA07/8376 Start Date*: 2007-12-04
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Does nebulised tobramycin (TOBI) via e-flow delivery systems cause a raised peak serum tobramycin level in children with Cystic Fibrosis?
    Medical condition: Children with cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004496-71 Sponsor Protocol Number: 104-201508 Start Date*: 2016-03-01
    Sponsor Name:Otonomy Inc.
    Full Title: A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere’...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000766-29 Sponsor Protocol Number: 104-201610 Start Date*: 2016-07-29
    Sponsor Name:Otonomy Inc.
    Full Title: A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE’S DISEASE
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003410-15 Sponsor Protocol Number: 6251 7976 Start Date*: 2005-11-21
    Sponsor Name:Neurology Unit
    Full Title: A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis.
    Medical condition: Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004840-51 Sponsor Protocol Number: EIP19-NFD-401 Start Date*: 2019-06-26
    Sponsor Name:EIP Pharma, Inc.
    Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)
    Medical condition: Early-Stage Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001573-28 Sponsor Protocol Number: Uni-Koeln-320 Start Date*: 2007-11-26
    Sponsor Name:Universität zu Köln
    Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.
    Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004410-42 Sponsor Protocol Number: C11-09 Start Date*: 2012-11-26
    Sponsor Name:Inserm
    Full Title: A phase I/II, open labeled, monocentric study of direct intracranial administration of a replication deficient adeno-associated virus gene transfer vector serotype rh.10 expressing the human ARSA c...
    Medical condition: Early onset forms of MLD
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    14.1 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002937-31 Sponsor Protocol Number: MA30143 Start Date*: 2017-09-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) BE (Completed) HU (Completed) PL (Completed) SK (Completed) ES (Ongoing) BG (Completed) SI (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001571-39 Sponsor Protocol Number: 1260 Start Date*: 2011-10-31
    Sponsor Name:University of Bristol
    Full Title: Investigating the relationship between sleep disturbance and learning in children with Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS): A Randomised Double-Blind Placebo-Controlled...
    Medical condition: Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS). (Also known as Benign Rolandic Epilepsy.)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10070530 Benign rolandic epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002987-57 Sponsor Protocol Number: AL002-LTE Start Date*: 2023-03-09
    Sponsor Name:Alector Inc.
    Full Title: A Multicenter, Long-Term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer’s Disease
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006113-34 Sponsor Protocol Number: XAMNPIOAP2011 Start Date*: 2013-10-24
    Sponsor Name:AURORA PUJOL ONOFRE
    Full Title: Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial.
    Medical condition: X-linked adrenoleukodystrophy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000127-36 Sponsor Protocol Number: KIH22001 Start Date*: 2023-04-04
    Sponsor Name:Karolinska Institutet
    Full Title: Evaluating rapamycin treatment in Alzheimer’s disease using positron emission tomography (ERAP)
    Medical condition: Alzheimer's disease (AD) and mild cognitive impairment (MCI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001252-35 Sponsor Protocol Number: DANA-2018-1. Start Date*: 2018-09-06
    Sponsor Name:Kirsten Møller
    Full Title: Neuroplasticity induced by general anaesthesia
    Medical condition: This trial investigates the effects of general anaesthesia on the helathy human brain. Thus, only healthy, young adults with no medical conditions will participate as volunteers in this study.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005262-35 Sponsor Protocol Number: 16401 Start Date*: 2013-07-08
    Sponsor Name:Bayer HealthCare AG
    Full Title: BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi...
    Medical condition: Clinically isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) PT (Completed) HU (Completed) CZ (Completed) NO (Completed) AT (Completed) FI (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001224-22 Sponsor Protocol Number: 215MS202 Start Date*: 2017-12-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002395-39 Sponsor Protocol Number: WN43174 Start Date*: 2022-05-24
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-...
    Medical condition: NMDAR or LGI1 mediated autoimmune Encephalitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:12:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA